The emergence of biologic therapies is arguably the greatest therapeutic advance in the care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at highly specific molecules shown to play critical roles in disease pathogenesis, with advantages in potency and selectivity. Furthermore, a large number of new biologic and small-molecule therapies in IBD targeting a variety of pathways are at various stages of development that should soon lead to a dramatic expansion in our therapeutic armamentarium. Additionally, since the initial introduction of biologics, there have been substantial advances in our understanding as to how biologics work, the practical realities of their administration, and how to enhance their efficacy and safety in the clinical setting. In this review, we will summarize the current state of the art for biological therapies in IBD, both in terms of agents available and their optimal use, as well as preview future advances in biologics and highly targeted small molecules in the IBD field.

中文翻译：

---

炎症性肠病生物疗法和新小分子的最新技术水平。

生物疗法的出现可以说是迄今为止在治疗炎症性肠病 (IBD) 方面取得的最大治疗进展，它允许针对在疾病发病机制中发挥关键作用的高度特异性分子进行定向治疗，并在效力和选择性方面具有优势。此外，针对 IBD 的多种途径的大量新的生物和小分子疗法正处于不同的发展阶段，这些疗法应该很快会导致我们的治疗设备急剧扩大。此外，自从最初引入生物制剂以来，我们对生物制剂的工作原理、其给药的实际情况以及如何提高其在临床环境中的有效性和安全性的理解有了实质性的进展。在这篇评论中，